← Leaderboards
Fakhrul Ahsan
Texas Tech University Health Scis Center
$7,151,998
Attributed
$7,151,998
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2006–24$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,151,998 · 6
By mechanism
R01$3,231,018 · 2
R42$2,628,172 · 1
R15$866,137 · 2
R43$426,671 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectLungPulmonary Artery StructureBlood VesselsPulmonary Arterial HypertensionPharmaceutical PreparationsScientistInnovationDevicesPharmacologic SubstanceBaseAnimal ModelDisease ProgressionPharmacotherapyCombined Modality TherapyBloodGenderResearch PersonnelCell ModelArterioleFunctional DisorderArterial RemodelingLesionHeart Failure
Grant awards (17)
PAH-on-a-chip: a novel disease-on-a-device model for studying the pathobiology of and screening drugs for pulmonary arterial hypertension$193,130
R43 · FY2024 · HL · contact PI
PAH-on-a-chip: a novel disease-on-a-device model for studying the pathobiology of and screening drugs for pulmonary arterial hypertension$233,541
R43 · FY2023 · HL · contact PI
Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH$1,006,870
R42 · FY2022 · HL · contact PI
Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patients$361,652
R01 · FY2022 · HL · contact PI
Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH$1,291,298
R42 · FY2021 · HL · contact PI
Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patients$365,632
R01 · FY2021 · HL · contact PI
Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patients$485,823
R01 · FY2020 · HL · contact PI
Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH$330,004
R42 · FY2020 · HL · contact PI
Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patients$510,112
R01 · FY2019 · HL · contact PI
Targetable and Inhalable Nanoparticle Based Combination Therapy for PAH$334,620
R01 · FY2018 · HL · contact PI
Targetable and Inhalable Nanoparticle Based Combination Therapy for PAH$45,677
R01 · FY2018 · HL · contact PI
Targetable and Inhalable Nanoparticle Based Combination Therapy for PAH$380,282
R01 · FY2017 · HL · contact PI
Targetable and Inhalable Nanoparticle Based Combination Therapy for PAH$380,266
R01 · FY2016 · HL · contact PI
Targetable and Inhalable Nanoparticle Based Combination Therapy for PAH$366,954
R01 · FY2015 · HL · contact PI
Anti-PAH Drugs in Inhalable Nanoparticles for Sustained Pulmonary Vasodilation$428,533
R15 · FY2010 · HL · contact PI
Long Circulating Low Molecular Weight Heparins Pulmonary$214,854
R15 · FY2006 · HL · contact PI
Alkylglycoside Mediated Pulmonary Delivery of Heparins$222,750
R15 · FY2004 · HL